Effects of low-dose ketamine infusion on remifentanil-induced acute opioid tolerance and the inflammatory response in patients undergoing orthognathic surgery

Kanta Kido¹, Shinichi Toda¹, Yuki Shindo¹, Hitoshi Miyashita², Shigekazu Sugino³, Eiji Masaki¹

¹Department of Dental Anesthesiology and Pain Management, Tohoku University Hospital, Sendai, Miyagi, Japan; ²Department of Oral Medicine and Surgery, Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University, Sendai, Miyagi, Japan; ³Department of Anesthesiology and Perioperative Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan

Purpose: Remifentanil is associated with acute opioid tolerance that can lead to increased postoperative consumption of opioid analgesics. The purpose of this study was to determine whether a low dose of ketamine prevents remifentanil-induced acute opioid tolerance and affects the neutrophil–lymphocyte ratio (NLR), a newly recognized biomarker of inflammation.

Materials and methods: Forty patients undergoing orthognathic surgery were enrolled in this prospective, randomized, double-blind study and randomly assigned to intraoperative administration of one of the following anesthetic regimens: high-dose remifentanil (0.6 µg/kg/minute); low-dose remifentanil (0.2 µg/kg/minute); or high-dose remifentanil with ketamine (remifentanil 0.6 µg/kg/minute with 0.5 mg/kg ketamine just after induction followed by an intraoperative infusion of ketamine 5 µg/kg/minute until wound closure). Fentanyl by intravenous patient-controlled analgesia was used for postoperative pain control. Visual Analog Scale pain scores and fentanyl consumption were recorded in the first 24 hours postoperatively. Perioperative serum C-reactive protein level and NLR were also determined.

Results: Baseline characteristics were similar in the three study groups. There were no between-group differences in Visual Analog Scale pain scores during the study period. The high-dose remifentanil group had a significantly higher requirement for fentanyl than the other two groups. Addition of ketamine did not affect the C-reactive protein level but increased the NLR; this increase was associated with decreased fentanyl consumption.

Conclusion: High-dose intraoperative remifentanil induced postoperative acute opioid tolerance that was prevented by infusion of low-dose ketamine. Ketamine increased the postoperative NLR associated with decreased fentanyl requirement for postoperative pain control.

Keywords: acute tolerance, central sensitization, NMDA receptor, neutrophil–lymphocyte ratio, remifentanil

Introduction

Perioperative pain management in patients who cannot undergo neuraxial regional block or peripheral nerve block continues to be challenging. Therefore, the options for pain control remain limited in many patients undergoing head and neck surgery under general anesthesia.

Opioids are the most common form of pain management both intraoperatively and postoperatively. Remifentanil is an ultra-short-acting µ-opioid receptor agonist that is often used for intraoperative analgesia because it has a rapid onset and offset,
thereby allowing easily controllable analgesia. Moreover, remifentanil can be used at a high dose and for a long duration to prevent intraoperative pain without delaying postoperative recovery or causing respiratory depression. However, exposure to high-dose remifentanil may paradoxically induce hyperalgesia and acute opioid tolerance, manifesting as more severe postoperative pain and greater analgesic requirements. A review by Angst found that postoperative acute opioid tolerance and/or hyperalgesia and increased opioid consumption were consistently reported when patients received a cumulative remifentanil dose >50 µg/kg intraoperatively.

The mechanism by which postoperative hyperalgesia/acute opioid tolerance induced is still not fully understood; so, there is no effective prevention or treatment strategy for hyperalgesia after remifentanil-based anesthesia. Several studies have identified central sensitization via the glutamnergic system and activation of the N-methyl-D-aspartate (NMDA) receptor to have significant roles in this mechanism. Ketamine is the most widely used NMDA receptor antagonist. It is thought to assist in the regulation of various pain states by desensitizing excitatory spinal cord NMDA receptors, thereby inhibiting pain transmission. It is known that use of high-dose ketamine for anesthesia has a dose-related stimulatory effect on the cardiovascular system, can cause psychiatric disturbance, and increases plasma cortisol concentrations. It has also been reported that intraoperative administration of low-dose ketamine can inhibit central sensitization and prevent opioid-induced hyperalgesia, thereby reducing opioid use and postoperative pain without undesirable effects. However, other studies could not confirm any effect of intraoperative ketamine on postoperative pain scores or opioid consumption, and two meta-analyses even concluded that ketamine could increase opioid-induced hyperalgesia. The effect of ketamine coadministration on remifentanil-induced hyperalgesia during craniofacial surgery has not been clarified.

Ketamine can also decrease the secretion of several proinflammatory mediators of inflammation and the immune response, including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-alpha, as well as production of C-reactive protein (CRP) and natural killer cell activity. Cytokine levels have been associated with development of hyperalgesia and nociceptive sensitivity. Furthermore, the neutrophil–lymphocyte ratio (NLR) has recently been proposed to be a sensitive biomarker of systemic inflammation. Measurement of the NLR might be a useful way for assessing the relationship between the inflammatory response and postoperative pain. However, few studies have examined the relationship of combined use of remifentanil and ketamine with the NLR and postoperative pain.

In this prospective randomized controlled study, we tested the following hypothesis: high-dose remifentanil induces acute opioid tolerance, whereas ketamine coadministration prevents it and reduces postoperative opioid consumption. In addition, ketamine modifies the postoperative side effect profile in orthognathic surgery. A secondary hypothesis was that ketamine administration affects immunoreactivity, which is associated with postoperative pain. The aims of this study were to determine whether intraoperative coadministration of ketamine prevents remifentanil-induced acute opioid tolerance postoperatively and to investigate the relevance of ketamine to the inflammatory response and postoperative opioid consumption in patients undergoing orthognathic surgery.

**Materials and methods**

**Patients**

This prospective randomized controlled study was approved by the Tohoku University Hospital Ethics Committee (approval number 26-46). Forty patients with an American Society of Anesthesiologists (ASA) physical status of I–II who were scheduled for mandibular orthognathic surgery were enrolled. The exclusion criteria were chronic use of analgesia, a psychiatric disorder, obesity (body mass index >30), a chronic inflammatory disease, and acute cardiovascular disease. Written informed consent was obtained from all patients and the study was conducted in accordance with the Declaration of Helsinki.

**Procedure**

All patients underwent the same surgical procedure, bilateral sagittal split ramus osteotomy for mandibular prognathism performed by two experienced surgeons. Before surgery, all patients were shown how to use a patient-controlled analgesia (PCA) pump (CADD-Legacy PCA, model 6300; Smiths Medical Japan, Tokyo, Japan) and how to rate their pain using a 100-mm Visual Analog Scale (VAS: 0, no pain; 100, worst pain).

Before induction of anesthesia, 6.6 mg of dexamethasone and 1.25 mg of droperidol were administered for prevention of postoperative nausea and vomiting (PONV). After a 3-minute infusion of remifentanil 0.4 µg/kg/minute, anesthesia was induced by propofol administered via a syringe pump (TE-371, Terumo Inc., Tokyo, Japan) with a built-in target-controlled infusion system (Diprifusor™, AstraZeneca,
London, UK). Rocuronium 0.8 mg/kg was then administered to facilitate nasotracheal intubation. All patients were mechanically ventilated with 40% oxygen after intubation to maintain end-tidal CO₂ of 35–40 mmHg. Anesthesia was maintained using remifentanil at the doses described below and by propofol administered as a target-controlled infusion to maintain a bispectral index of 40–60.

Patients were randomly assigned, in a double-blinded fashion, to one of three groups (12 patients/group).14 Before the study started, a random-number table was generated, specifying the group to which each patient would be assigned upon entry into the trial. For each patient, an envelope containing the group assignment was prepared, sealed, and sequentially numbered.

On the morning of surgery, an anesthesiologist not involved in evaluation of the patient opened the patient’s allocated envelope and prepared the assigned syringes containing remifentanil, ketamine, and/or saline solution. All the other study investigators were blinded to group allocation. The three treatment groups are described below.

High-dose remifentanil group
A higher dose of remifentanil than usual is often used for craniofacial surgery to control pain and hemodynamics. In this study, patients in the high-dose remifentanil group received an intraoperative infusion of remifentanil 0.6 µg/kg/minute. According to a review article on remifentanil-induced hyperalgesia,4 postoperative acute opioid tolerance, hyperalgesia, and increased opioid consumption are more likely to occur if the cumulative intraoperative remifentanil dose is >50 µg/kg. In this trial, a high dose of remifentanil was calculated to be 0.6 µg/kg/minute on the basis of the findings of a pilot study in which we took into account patient body weight and duration of surgery. The cumulative dose of remifentanil that would induce hyperalgesia was calculated to be 50 µg/kg ×55 kg = 2,750 µg. In this protocol, the total dose of remifentanil in the high-dose group was expected to be 0.6 µg/kg/minute ×55 kg ×90 minutes = 2,970 µg.

Low-dose remifentanil group
These patients received an intraoperative infusion of remifentanil 0.2 µg/kg/minute.

High-dose remifentanil with ketamine group
These patients received an intraoperative infusion of remifentanil 0.6 µg/kg/minute with ketamine 0.5 mg/kg administered immediately after induction of anesthesia as a loading dose followed by a maintenance infusion of 5 µg/kg/minute until completion of surgery.14,21

Inadequate anesthesia was defined as a heart rate that exceeded the baseline value by 15% and/or a systolic blood pressure that exceeded the baseline value by 20% for 1 minute or longer. The remifentanil concentration was increased stepwise by 0.05 µg/kg/minute when inadequate anesthesia was suspected. When persistent hypotension (defined as a systolic blood pressure <80 mmHg or a mean arterial pressure <60 mmHg) was observed, an intravenous bolus dose of ephedrine was administered. Bradycardia (defined as a heart rate <50 beats/minute) was treated with atropine. Fentanyl 4 µg/kg and flurbiprofen axetil 1 mg/kg were administered intravenously at the end of surgery. After cessation of propofol and remifentanil, the trachea was extubated when the patient could respond to verbal commands, such as gripping the hand of the anesthesiologist, and had a spontaneous respiratory rate >10 breaths/minute, a tidal volume >8 mL/kg, and an end-tidal CO₂ partial pressure of <50 mmHg. Postoperative analgesia consisted of fentanyl delivered via a PCA pump containing 500–700 µg fentanyl in a total volume of 50–70 mL saline (giving a final fentanyl concentration of 10 µg/mL). The PCA device was set to deliver fentanyl 0.5 µg/kg as a bolus dose with a 6-minute-lockout interval. Continuous infusion was not used. This PCA regimen was continued for 24 hours after surgery. Flurbiprofen axetil 50 mg could be administered as rescue analgesia if requested by the patient.

Measurements
Primary outcome measures were pain severity, fentanyl consumption, and the number of PCA demands in the first 24 hours after surgery. The secondary outcome measures were the CRP level, neutrophil and lymphocyte counts, and the NLR, all of which are indicators of the inflammatory response.34 The total doses of remifentanil and propofol administered during surgery were recorded. Pain intensity was assessed using the VAS scores recorded before leaving the operating room and at 1, 3, 6, 12, and 24 hours after surgery. Anesthesia-related complications, including PONV, respiratory depression (<10 breaths/minute or SpO₂ <92%), hallucinations, and diplopia, were recorded. PONV was treated by an intravenous bolus of metoclopramide 10 mg. The CRP level and NLR were determined from blood samples taken preoperatively and on days 1 and 7 postoperatively. The NLR was determined by the absolute neutrophil count divided by the absolute lymphocyte count. Body temperature was recorded at each assessment point. Surgical-site infections that occurred in the first postoperative week were also recorded.
Statistical analyses
Our sample size estimation was based on the differences in 24-hour fentanyl consumption expected between the high-dose and low-dose remifentanil groups. In our pilot study of five patients, the fentanyl consumption was approximately 400 µg (SD 200 µg) in the first 24 hours postoperatively in the high-dose remifentanil group. Using G*power software version 3.0.10 for Mac (Heinrich-Heine-Universität, Düsseldorf, Germany) with an α error of 0.05 for detecting a 50% difference in fentanyl consumption, we estimated that a sample size of 12 patients per treatment group would be required. Post hoc calculation of the achieved power was 0.8. Allowing for a dropout rate of 10%, the total number of patients needed was set at 40. The Kolmogorov–Smirnov test was used to determine normality. Fentanyl consumption and the number of PCA demands were compared between the three groups by one-way analysis of variance and the total dose of remifentanil and propofol were compared using the Kruskal–Wallis test. The VAS score, CRP value, neutrophil and lymphocyte count, and NLR at each time point were compared among the three groups using two-way analysis of variance. The Tukey’s test was used as needed for post hoc comparisons. The Chi-squared test was used for categorical variables (sex, ASA physical status, and the number of patients who needed the drugs). Correlations between fentanyl consumption and the NLR on postoperative day 1 were calculated using the Spearman’s rank correlation test. The statistical analyses were performed using GraphPad Prism 6 for Mac (GraphPad Software Inc., San Diego, CA, USA). A P-value <0.05 was considered statistically significant.

Results
Forty patients were enrolled in this study. One patient was excluded because of a psychiatric disorder and three patients were withdrawn because of the need for an additional surgical procedure (n=1; high-dose remifentanil group), postoperative bleeding requiring repeat surgery (n=1; low-dose remifentanil group), and refusal to use PCA (n=1; high-dose remifentanil with ketamine group). Patient characteristics (age, height, weight, body mass index, sex, and ASA status) were not significantly different between the three study groups (Table 1). The duration of surgery and anesthesia; total doses of propofol administered; total amount of bleeding; number of patients who needed atropine, ephedrine, and postoperative rescue analgesia (flurbiprofen axetil); and incidence of PONV were comparable between the groups (Table 2).

Table 1 Patient characteristics
<table>
<thead>
<tr>
<th></th>
<th>High-dose remifentanil (n=12)</th>
<th>Low-dose remifentanil (n=12)</th>
<th>High-dose remifentanil with ketamine (n=12)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>28±13</td>
<td>25±5</td>
<td>25±9</td>
<td>0.638</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>161±7</td>
<td>159±10</td>
<td>163±9</td>
<td>0.527</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>58±14</td>
<td>53±8</td>
<td>55±12</td>
<td>0.517</td>
</tr>
<tr>
<td>BMI (kg m⁻²)</td>
<td>22.4±3.8</td>
<td>20.9±1.9</td>
<td>20.7±3.0</td>
<td>0.332</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>4/8</td>
<td>1/11</td>
<td>4/8</td>
<td>0.264</td>
</tr>
<tr>
<td>ASA PS I/II</td>
<td>9/3</td>
<td>12/0</td>
<td>10/2</td>
<td>0.197</td>
</tr>
</tbody>
</table>

Notes: Data are shown as the mean±SD or as the number of patients. There were no statistically significant differences between the study groups.
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists; PS, physical status.

Table 2 Characteristics of the surgical procedure, postoperative rescue analgesic use, and PONV
<table>
<thead>
<tr>
<th></th>
<th>High-dose remifentanil (n=12)</th>
<th>Low-dose remifentanil (n=12)</th>
<th>High-dose remifentanil with ketamine (n=12)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of surgery (minutes)</td>
<td>113 (96–152)</td>
<td>93 (80–112)</td>
<td>105 (88–116)</td>
<td>0.071</td>
</tr>
<tr>
<td>Duration of anesthesia (minutes)</td>
<td>177 (155–213)</td>
<td>152 (142–167)</td>
<td>160 (142.3–180.8)</td>
<td>0.091</td>
</tr>
<tr>
<td>Total dose of remifentanil (µg/kg)</td>
<td>81.8 (66.7–93.1)</td>
<td>32.5 (27.5–37.1)</td>
<td>72.6 (64.1–78.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total dose of propofol (mg/kg)</td>
<td>16.5 (15.0–22.4)</td>
<td>15.9 (15.1–18.3)</td>
<td>17.1 (15.7–18.7)</td>
<td>0.560</td>
</tr>
<tr>
<td>Total bleeding (mL)</td>
<td>111 (53–151)</td>
<td>96 (72–139)</td>
<td>87 (71–132)</td>
<td>0.582</td>
</tr>
<tr>
<td>Use of atropine, no. of patients</td>
<td>8</td>
<td>6</td>
<td>10</td>
<td>0.223</td>
</tr>
<tr>
<td>Use of ephedrine, no. of patients</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.589</td>
</tr>
<tr>
<td>Rescue medication</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0.336</td>
</tr>
<tr>
<td>No. of patients with PONV</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>0.197</td>
</tr>
</tbody>
</table>

Notes: Data are shown as the median (interquartile range) or number of patients as appropriate. *P<0.05 vs the high-dose remifentanil group and the high-dose remifentanil with ketamine group.
Abbreviation: PONV, postoperative nausea and vomiting.
dose of remifentanil administered in the two high-dose remifentanil groups was as planned (ie, >50 µg/kg). There were no postoperative complications in any of the study groups.

VAS pain scores did not differ significantly between the three groups at any of the assessment time points in the 24 hours postoperatively (Figure 1A), indicating that the PCA pump was appropriate for postoperative pain management. Fentanyl consumption was significantly greater in the first 24 hours postoperatively in the high-dose remifentanil group (4.65±3.34 µg) than in the low-dose remifentanil group (2.41±1.06 µg; P<0.05) and the high-dose remifentanil with ketamine group (1.65±1.62 µg; P<0.01; Figure 1B). Similarly, the number of PCA demands was significantly greater in the high-dose remifentanil group (12.8±9.3) than in the low-dose remifentanil group (5.9±2.3; P<0.05) and the high-dose remifentanil with ketamine group (4.8±5.0; P<0.05) (Figure 1C).

Perioperative inflammatory response was compared between the study groups using the CRP level, neutrophil and lymphocyte counts, and the NLR as inflammatory biomarkers (Table 3). There was no significant difference in the CRP level or neutrophil count preoperatively or on postoperative days 1 and 7 between the groups. The lymphocyte count was significantly lower in the high-dose remifentanil with ketamine group than in the high-dose remifentanil group on postoperative day 1 (P<0.05; 0.8±0.3×10^3/µL vs 1.2±0.3×10^3/µL). On postoperative day 1, NLR in the high-dose remifentanil with ketamine group was significantly higher than that in the high-dose remifentanil group and also higher than that in the low-dose remifentanil group (P<0.001 vs the high-dose remifentanil group, P<0.05 vs the low-dose remifentanil group). To investigate the clinical significance of the NLR changes, we tested correlations between postoperative fentanyl consumption and pre- and postoperative NLR levels in all patients using Spearman’s rank-order correlation (Table 4); no significant correlation was found and the correlation coefficients were 0.07 and –0.06, respectively. There was no significant difference in body temperature between the study groups (data not shown), and there were no surgical-site infections. In addition, no side effects induced by ketamine including hallucination or diplopia were observed in the ketamine group.

**Figure 1** Postoperative VAS pain scores, fentanyl consumption, and number of PCA demands via intravenous fentanyl within 24 hours.

**Notes:** Postoperative VAS pain score (A), fentanyl consumption (B), and number of PCA demands (C). Results are expressed as the mean±SD. *P<0.05, **P<0.01.

**Abbreviations:** PCA, patient-controlled analgesia; VAS, Visual Analog Scale.
**Discussion**

The findings of this study indicate that intraoperative coadministration of ketamine decreases the likelihood of remifentanil-induced postoperative acute opioid tolerance without adverse effects and significantly increases the NLR in 24 hours following the orthognathic surgery. Therefore, low-dose ketamine could be useful for prevention of the acute postoperative opioid tolerance associated with remifentanil-based anesthesia in patients undergoing orthognathic surgery.

In this study, intraoperative coadministration of ketamine decreased the risk of development of remifentanil-induced acute postoperative opioid tolerance without adverse effects in patients undergoing orthognathic surgery. It is widely known that exposure to high-dose remifentanil is associated with postoperative hyperalgesia and acute opioid tolerance that manifests as increased postoperative pain intensity and greater analgesic requirements.3–7 However, distinguishing between postoperative hyperalgesia and acute tolerance in the clinical setting is challenging.8 In this study, we considered postoperative fentanyl consumption as indicative of the development of acute tolerance,4 because von Frey filaments could not effectively be applied to the intraoral incision and surrounding area to assess the pain threshold and extent.27 Although the detailed mechanism underlying the hyperalgesia (or opioid tolerance) is not fully understood, the most effective strategies for prevention of remifentanil-induced hyperalgesia in animal models have focused on central sensitization via the glutaminergic system and activation of the NMDA receptor.9,11,12,35 Coadministration of morphine and MK-801, a noncompetitive NMDA receptor antagonist, or LY274614, a competitive NMDA receptor antagonist, prevented hyperalgesia or opioid tolerance in the isolated rat spinal cord36 and other animals.37,38 Indeed, administration of an NMDA antagonist, such as ketamine or magnesium, has been shown to attenuate remifentanil-induced hyperalgesia in several human studies.5,8,15,19,39–41 A meta-analysis of 14 randomized controlled trials that included 729 patients concluded that perioperative administration of an NMDA receptor antagonist attenuated the increase in postoperative pain intensity and opioid consumption and increased patient satisfaction without increasing adverse effects.23 Although these clinical studies did not include patients undergoing intraoral or maxillofacial surgery, in whom the options for

---

**Table 3** Perioperative CRP, neutrophil and lymphocyte counts, and NLR

<table>
<thead>
<tr>
<th></th>
<th>High-dose remifentanil (n=12)</th>
<th>Low-dose remifentanil (n=12)</th>
<th>High-dose remifentanil with ketamine (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>POD1</td>
<td>4.1±1.8</td>
<td>3.4±1.8</td>
<td>3.9±1.3</td>
</tr>
<tr>
<td>POD7</td>
<td>0.5±0.6</td>
<td>0.4±0.8</td>
<td>0.6±0.9</td>
</tr>
<tr>
<td>Neutrophils (×1,000/µL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>3.4±0.9</td>
<td>3.2±1.4</td>
<td>3.0±0.8</td>
</tr>
<tr>
<td>POD1</td>
<td>15.6±2.4</td>
<td>14.9±3.0</td>
<td>14.9±3.3</td>
</tr>
<tr>
<td>POD7</td>
<td>6.0±2.2</td>
<td>4.5±2.1</td>
<td>4.5±2.1</td>
</tr>
<tr>
<td>Lymphocytes (×1,000/µL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>2.0±0.4</td>
<td>2.1±0.6</td>
<td>1.8±0.3</td>
</tr>
<tr>
<td>POD1</td>
<td>1.2±0.3</td>
<td>1.0±0.3</td>
<td>0.8±0.3*</td>
</tr>
<tr>
<td>POD7</td>
<td>1.9±0.5</td>
<td>2.1±0.5</td>
<td>1.8±0.4</td>
</tr>
<tr>
<td>NLR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>1.8±0.5</td>
<td>1.6±0.7</td>
<td>1.7±0.6</td>
</tr>
<tr>
<td>POD1</td>
<td>14.0±3.8</td>
<td>15.8±4.4</td>
<td>19.0±6.6‡§</td>
</tr>
<tr>
<td>POD7</td>
<td>3.7±2.6</td>
<td>2.2±0.9</td>
<td>2.6±1.3</td>
</tr>
</tbody>
</table>

**Notes:** Results are expressed as the mean±SD. *P<0.05 vs the high-dose remifentanil group. †P<0.05 vs the low-dose remifentanil group. ‡P<0.001 vs the high-dose remifentanil group.

**Abbreviations:** CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio; POD, postoperative day.

---

**Table 4** Correlation between fentanyl consumption and NLR

<table>
<thead>
<tr>
<th>Fentanyl consumption</th>
<th>NLR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative</td>
<td>r 0.07</td>
</tr>
<tr>
<td></td>
<td>P 0.67</td>
</tr>
<tr>
<td></td>
<td>n 36</td>
</tr>
<tr>
<td>Postoperative day 1</td>
<td>r −0.06</td>
</tr>
<tr>
<td></td>
<td>P 0.72</td>
</tr>
<tr>
<td></td>
<td>n 36</td>
</tr>
</tbody>
</table>

**Note:** Spearman’s rank correlation test.

**Abbreviations:** NLR, neutrophil–lymphocyte ratio; r, correlation coefficient; n, number of subjects.
pain control are limited, our findings confirm that low-dose ketamine is effective for decreasing acute postoperative opioid tolerance even in patients undergoing orthognathic surgery without undesirable complications. Leal et al\textsuperscript{31} recently reported that low-dose ketamine did not prevent remifentanil-induced hyperalgesia after laparoscopic cholecystectomy. However, in their study, the intraoperative dose of remifentanil was \(<50\ \mu g/kg\textsuperscript{,2} lower than that used in our study. Therefore, there was a possibility that remifentanil did not adequately induce postoperative hyperalgesia in their study. Another study reported that intraoperative low-dose ketamine did not prevent remifentanil-induced acute opioid tolerance after scoliosis surgery.\textsuperscript{29} However, the participants in that study were adolescents aged 12–18 years, in whom the pharmacokinetics of ketamine may be different from those in the adults who participated in our study. Overall, our findings suggest that an infusion of ketamine could prevent acute postoperative opioid tolerance in adult patients undergoing orthognathic surgery. Therefore, coadministration of ketamine could be considered if administration of high-dose remifentanil \((\geq 50\ \mu g/kg)\) is part of the anesthetic plan.

In addition, a low dose of ketamine significantly increased the NLR on day 1 after surgery in this study. It is well known that ketamine decreases inflammation and the immune response, including secretion of several pro-inflammatory mediators.\textsuperscript{24–26,42,43} Moreover, attenuation of cytokine secretion has been shown to decrease the intensity of hyperalgesia, nociceptive sensitivity, and postoperative pain.\textsuperscript{28–30,32,44} Therefore, we used the NLR, a newly identified sensitive biomarker of inflammation, to assess whether coadministration of ketamine is associated with inflammation, the immune response, and postoperative pain. Our results suggest that ketamine has immunosuppressive effects, as indicated by a decrease in the number of lymphocytes; however, the composition of lymphocytes was not examined in this study. Ketamine at a low concentration has been shown in vitro to trigger apoptosis in T lymphocytes via the mitochondrial pathway\textsuperscript{45} and has also been reported to decrease the count and activity of natural killer cells after exposure in vivo.\textsuperscript{46,47} These studies might be able to explain at least in part the postoperative reduction in the lymphocyte count in this study. Only one study has investigated the relationship between the preoperative NLR and postoperative pain in patients undergoing laparoscopic cholecystectomy.\textsuperscript{48} That study showed that a higher preoperative NLR was associated with lower analgesic requirements. Our finding that a high ketamine-induced postoperative NLR was associated with decreased postoperative opioid consumption might also help to shed light on the mechanism by which ketamine prevents remifentanil-induced acute opioid tolerance.

However, we found no significant difference in the CRP level between the three study groups. This result is consistent with a meta-analysis that found administration of ketamine and production of cytokines did not cause changes in the CRP level.\textsuperscript{26} Ketamine may produce an immunosuppressive response rather than an anti-inflammatory response in patients undergoing remifentanil-based anesthesia.

**Limitations**

This study has several limitations. First, we did not include a control group receiving normal saline to confirm whether low-dose remifentanil induces postoperative acute opioid tolerance. However, it would be unethical to withhold opioids in patients undergoing this type of surgery. Second, only the NLR was used to assess the inflammatory response. Therefore, a further study is needed to determine the relationship between the NLR and other markers of inflammation. Also, we examined the NLR at only three time points: preoperatively, POD1, and POD7. It is also necessary to examine NLR at other time points, such as intraoperatively or at POD3, to evaluate the correlation between ketamine administration and NLR, and the associated clinical significance. Further study is thus needed. Third, we used dexamethasone and flurbiprofen axetil to control postoperative pain and PONV in the immediate postoperative period in all patients. Both these drugs have an anti-inflammatory effect, so the possibility that they could have affected the NLR cannot be excluded. Fourth, the high-dose remifentanil group might have undergone more invasive surgeries than the high-dose remifentanil with ketamine group based on the longer operative time and higher bleeding, although there were no statistically significant differences in both groups. Also, 8% of participants in the low-dose remifentanil group were males vs 33% in each of the two other groups. These factors might partly explain the differences in fentanyl requirement among the three groups.

**Conclusion**

Administration of low-dose ketamine \((0.5\ \text{mg/kg}+5\ \mu g/kg/\text{minute})\) during remifentanil-based anesthesia decreased acute opioid tolerance in the 24 hours following orthognathic surgery. There was also an association between decreased postoperative fentanyl consumption after administration of ketamine and an increase in the NLR. Further studies are needed to determine the clinical significance of the changes in NLR brought about by ketamine.
Acknowledgment
The authors would like to thank Drs. Atsuko Matoba and Makoto Yasuda for useful discussions and data collection.

Author contributions
All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
4. Kim SH, Lee MH, Seo H, Lee IG, Hong JY, Hwang JH. Intraoperative infusion of 0.6-0.9 µg·kg⁻¹·min⁻¹ remifentanil induces acute tolerance in young children after laparoscopic ureteroneocystostomy. Anesthesiology. 2013;118(2):337–343.


